Barclays
FULC icon

Barclays’s Fulcrum Therapeutics FULC Stock Holding History

Barclays’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Sell
83,373
-5,085
-6% -$30.9K ﹤0.01% 3491
2026
Q1 		$678K Sell
88,458
-44,083
-33% -$409K ﹤0.01% 2994
2025
Q4 		$1.5M Buy
132,541
+42,925
+48% +$437K ﹤0.01% 3136
2025
Q3 		$824K Sell
89,616
-22,447
-20% -$162K ﹤0.01% 3487
2025
Q2 		$771K Buy
112,063
+29,606
+36% +$158K ﹤0.01% 3506
2025
Q1 		$237K Sell
82,457
-39,613
-32% -$146K ﹤0.01% 3946
2024
Q4 		$574K Sell
122,070
-2,071
-2% -$7.64K ﹤0.01% 3741
2024
Q3 		$443K Buy
124,141
+97,565
+367% +$724K ﹤0.01% 3856
2024
Q2 		$165K Sell
26,576
-44,939
-63% -$340K ﹤0.01% 3678
2024
Q1 		$675K Buy
71,515
+3,330
+5% +$29.7K ﹤0.01% 3403
2023
Q4 		$460K Buy
+68,185
New +$303K ﹤0.01% 3927
2023
Q3 		– Sell
-144,983
Closed -$478K – 4631
2023
Q2 		$478K Buy
144,983
+117,730
+432% +$346K ﹤0.01% 2778
2023
Q1 		$77.7K Buy
27,253
+15,561
+133% +$139K ﹤0.01% 4300
2022
Q4 		$85.1K Buy
11,692
+10,244
+707% +$66.8K ﹤0.01% 4320
2022
Q3 		$12K Sell
1,448
-265
-15% -$1.9K ﹤0.01% 4231
2022
Q2 		$8K Sell
1,713
-21,667
-93% -$212K ﹤0.01% 4686
2022
Q1 		$553K Buy
+23,380
New +$331K ﹤0.01% 2838

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's FULC Position: Q2 2026 in Review

Barclays reduced its Fulcrum Therapeutics (FULC) stake by 5.7% in Q2 2026, selling an estimated $30.9K and leaving 83,373 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #3491.

Barclays first reported a position in FULC in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.5M in Q4 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Barclays held 83,373 shares of Fulcrum Therapeutics worth $305K as of Q2 2026.
  • Barclays sold 5,085 Fulcrum Therapeutics shares in Q2 2026, an estimated $30.9K.
  • Fulcrum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3491 holding.
  • Barclays first reported a position in Fulcrum Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Fulcrum Therapeutics position peaked at $1.5M in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.